^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Source:
Title:

Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.

Published date:
05/25/2023
Excerpt:
CONTRADICTING EVIDENCE: Of pts with BRAF-fusions, a pt with AGK-BRAF-fused melanoma had CR (DoR 51.8+ months); 46% (6/13) had SD….As single agent anticancer therapy, FORE8394 had antitumor activity in various tumors with BRAF alterations, including pts previously treated with MAPKi and pts with BRAF fusions.
DOI:
10.1200/JCO.2023.41.16_suppl.3006
Evidence Level:
Resistant: D – Preclinical
New
Source:
Title:

Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses

Excerpt:
Heterogeneous patterns of drug response to RAF and MEK inhibitors of cell lines harboring BRAF fusions compared toBRAFV600E mutant lines...Cell lines with BRAF fusions, except SK-MEL-23, demonstrated resistance to PLX8394, a BRAF inhibitor developed as a “paradox breaker...
DOI:
10.1016/j.celrep.2019.09.009